Alzheimer's drug extension trial halted early — what we know
NCT ID NCT05522387
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study gave Alzheimer's patients who had already completed earlier XPro1595 trials an extra 55 to 74 weeks of the drug to check long-term safety and effects on memory and brain health. Only 11 people took part, and the trial was terminated early, so the findings are limited. The drug targets brain inflammation, but whether it helps slow Alzheimer's remains uncertain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XPro1595 (a weekly injection that targets brain inflammation)
What this could lead to
If it works, this could point toward a treatment that slows cognitive decline in Alzheimer's disease.
What could go wrong
The study was terminated early with only 11 participants, so results are very limited. It is unclear if XPro1595 provides meaningful benefit, and side effects remain a risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Health
Ivanhoe, Victoria, 3079, Australia
-
Australian Alzheimer's Research Foundation
Perth, Western Australia, 6009, Australia
-
KaRa MINDS
Macquarie Park, New South Wales, 2113, Australia
-
Neuro Trials Victoria Pty Ltd T/A NeuroCentrix
Carlton, Victoria, 3053, Australia